Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Change in Receivables (2021 - 2025)

Keros Therapeutics posted quarterly Change in Receivables of $75000.0 for Q4 2025, down 96.81% year-on-year from $2.4 million in Q4 2024, and up 100.61% on a QoQ basis from -$12.3 million in Q3 2025.

Keros Therapeutics (KROS) has 5 years of Change in Receivables data on file, last reported at $75000.0 in Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables fell 96.81% year-over-year to $75000.0; the trailing twelve-month figure through Dec 2025 stood at $825000.0 (down 68.26% YoY), and the FY2025 full-year result was $825000.0, down 68.26% from the prior year.
  • Change in Receivables for Q4 2025 stood at $75000.0, up from -$12.3 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $18.0 million in Q4 2021 and bottomed at -$18.0 million in Q1 2022.
  • The 5-year median for Change in Receivables is $83000.0 (2024), against an average of $274384.6.
  • Peak annual rise in Change in Receivables reached 17428.92% in 2025, while the deepest fall reached 3309.38% in 2025.
  • A 5-year view of Change in Receivables shows it stood at $18.0 million in 2021, then sank by 200.0% to -$18.0 million in 2022, then jumped by 100.79% to $143000.0 in 2023, then jumped by 1546.15% to $2.4 million in 2024, then sank by 96.81% to $75000.0 in 2025.
  • The last three Change in Receivables figures came in at $75000.0 (Q4 2025), -$12.3 million (Q3 2025), and -$1.5 million (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 208,524.00
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -39.80 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -1.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 110.42 Mn
10 Keros Therapeutics 403.85 Mn 116.45 Mn - 75,000.00

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 75,000.00
Dec 31, 2025 75,000.00
Sep 30, 2025 -12.32 Mn
Sep 30, 2025 -12.32 Mn
Jun 30, 2025 -1.48 Mn
Jun 30, 2025 -1.48 Mn
Mar 31, 2025 14.55 Mn
Mar 31, 2025 14.55 Mn
Dec 31, 2024 2.35 Mn
Dec 31, 2024 2.35 Mn
Sep 30, 2024 384,000.00
Sep 30, 2024 384,000.00
Jun 30, 2024 -222,000.00
Jun 30, 2024 -222,000.00
Mar 31, 2024 83,000.00
Mar 31, 2024 83,000.00
Dec 31, 2023 143,000.00
Dec 31, 2023 143,000.00
Mar 31, 2022 -18.00 Mn
Mar 31, 2022 -18.00 Mn
Dec 31, 2021 18.00 Mn
Dec 31, 2021 18.00 Mn
Sep 30, 2021 -100,000.00
Sep 30, 2021 -100,000.00
Jun 30, 2021 100,000.00
Jun 30, 2021 100,000.00